Kala Pharmaceuticals, Inc. (trading as KALA BIO, Inc.) is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare and severe eye diseases. The company utilizes proprietary nanoparticle-based mucus penetrating particles technology in its research pipeline. Its lead clinical candidate, KPI-012, a human mesenchymal stem cell secretome therapy, was evaluated in the Phase 2b CHASE trial for persistent corneal epithelial defect, though the trial did not achieve its primary endpoints. The company also has preclinical programs including KPI-014 for rare inherited retinal diseases. Recently, Kala Pharmaceuticals has pursued a strategic shift by entering into an exclusive license agreement for Researgency, a proprietary AI infrastructure platform designed for biotech research and development workflows. This dual-focus approach positions the company at the intersection of clinical drug development and enterprise artificial intelligence solutions for the biotech industry. Headquartered in Arlington, Massachusetts and founded in 2009, Kala Pharmaceuticals operates as both an ophthalmology-focused therapeutic developer and an emerging AI platform provider.